SANOFI (SNW.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:SNW • FR0000120578
SNW.DE Key Statistics, Chart & Performance
The current stock price of SNW.DE is 80.72 EUR. In the past month the price decreased by -0.77%. In the past year, price decreased by -21.93%.
SNW.DE Technical Analysis
SNW.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SNW.DE. SNW.DE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
SNW.DE Financial Highlights
Over the last trailing twelve months SNW.DE reported a non-GAAP Earnings per Share(EPS) of 7.04. The EPS decreased by -8.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
SNW.DE Forecast & Estimates
29 analysts have analysed SNW.DE and the average price target is 101.29 EUR. This implies a price increase of 25.49% is expected in the next year compared to the current price of 80.72.
For the next year, analysts expect an EPS growth of 20.15% and a revenue growth 6.49% for SNW.DE
SNW.DE Ownership
SNW.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.45 | 194.74B | ||
| SAN.PA | SANOFI | 11.52 | 195.83B | ||
| MRK.DE | MERCK KGAA | 14.41 | 53.46B | ||
| UNC.DE | UCB SA | 40.65 | 50.77B | ||
| UCB.BR | UCB SA | 40.65 | 50.77B | ||
| BAYN.DE | BAYER AG-REG | 8.48 | 44.47B | ||
| 1BAYN.MI | BAYER AG-REG | 8.4 | 44.05B | ||
| IPN.PA | IPSEN | 13.25 | 11.41B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 107.45 | 9.95B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.32 | 10.02B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 19.91 | 8.34B | ||
| VIRP.PA | VIRBAC SA | 20.16 | 2.93B |
Related stock screener links
About SNW.DE
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 84587
Phone: 33153774000
SANOFI / SNW.DE FAQ
Can you describe the business of SANOFI?
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
What is the stock price of SANOFI today?
The current stock price of SNW.DE is 80.72 EUR. The price increased by 1.89% in the last trading session.
Does SANOFI pay dividends?
SANOFI (SNW.DE) has a dividend yield of 5.35%. The yearly dividend amount is currently 3.79.
What is the ChartMill technical and fundamental rating of SNW stock?
SNW.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in SANOFI be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNW.DE.
What is the expected growth for SNW stock?
The Revenue of SANOFI (SNW.DE) is expected to grow by 6.49% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is SANOFI worth?
SANOFI (SNW.DE) has a market capitalization of 194.96B EUR. This makes SNW.DE a Large Cap stock.